Low-intensity extracorporal shockwave therapy for Peyronie’s disease

Cover Page

Cite item

Full Text

Abstract

  • The article is devoted to the study of the effectiveness of low-intensity extracorporal shockwave therapy in the treatment of Peyronie disease. Fibroplastic induration of the penis, i.e Peyronie disease, is the one with poorly studied aetiology and pathogenesis. Treatment algorithm also needs to be studied. Literature review was performed. Examination and treatment of patients with the use of low-intensity extracorporeal shock wave therapy was performed. The results of our own research have confirmed the high efficiency and safety of the method.

About the authors

Evgeniy S. Gubanov

Medical University “Reaviz”

Author for correspondence.
Email: samara-urology@mail.ru

Urologist, Candidate of Medical Sciences, Associate Professor, Department of Surgical Diseases

Russian Federation, Samara

Evgeniy A. Boryaev

Medical University “Reaviz”

Email: boriaev.evgeny@yandex.ru

Urologist

Russian Federation, Samara

Sergey A. Stolyarov

Medical University “Reaviz”

Email: stolyarovsamara@mail.ru

Doctor of Medical Sciences, Head of the Department of Surgical Diseases

Russian Federation, Samara

Alexander A. Zimichev

Samara State Medical University

Email: Zimichev@mail.ru

Doctor of Medical Sciences, Professor, Department of Urology

Russian Federation, Samara

References

  1. Vinogradov IV, Logvinov LA, Kumachev KV, et al. Swlt in peyronies disease patients. Andrologiya i genital’naya hirurgiya. 2011;12(3):27–31. (In Russ.)
  2. Garilevich BA, Kirpatovskij VI, Semenov AA, Kudryavceva LV. Experimental substantiation of the possibility of using low energy acoustic shock waves in the therapy of various urological diseases. Experimental and clinical urology. 2018;(2):4–10. (In Russ.)
  3. Kasenova BZh, Notov IK, Verdiev RV, et al. Current issues of pathogenesis, diagnostic visualization and methods of treatment peyronie’s disease. RUDN journal of medicine. 2020;24(1):9–25. (In Russ.) doi: 10.22363/2313-0245-2020-24-1-9-25
  4. Maley M. Fransua Peyroni – leyb-medik korolya, zalozhivshiy fundament budushchego urologii. Meditsinskie aspekty zdorovya muzhchin. 2014;4(15):61–63. (In Russ.)
  5. Moskaleva YuS, Ostapchenko AYu, Korneev IA. Peyronie’s disease. Urologicheskie vedomosti. 2015;5(4):30–35. (In Russ.) doi: 10.17816/uroved5430-35
  6. Nejmark AI, Astahov YuI, Sidor MV. Extracorporeal shock-wave therapy in the treatment of peyronie’s disease. Urologiia. 2004;(2):33–36. (In Russ.)
  7. Pakus OI. Effektivnost’ distancionnoj udarno-volnovoj terapii pri bolezni Pejroni [dissertation abstract]. Moscow; 2005. (In Russ.)
  8. Scheplev PA, Danilov IA, Kolotinskij AB, et al. Klinicheskie rekomendacii. Bolezn’ Pejroni. Andrologiya i genital’naya hirurgiya. 2007;8(1):55–58. (In Russ.)
  9. Al-Thakafi S, Al-Hathal N. Peyronie’s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl Androl Urol. 2016;5(3):280–289. doi: 10.21037/tau.2016.04.05
  10. Arafa M, Eid H, El-Badry A, et al. The prevalence of Peyronie’s disease in diabetic patients with erectile dysfunction. Int J Impot Res. 2007;19(2):213–217. doi: 10.1038/sj.ijir.3901518
  11. Bella AJ, Lee JC, Grober ED, et al. Canadian Urological Association guideline for Peyronie’s disease and congenital penile curvature. Can Urol Assoc J. 2018;12(5):E197–E209. doi: 10.5489/cuaj.5255
  12. Berookhim BM, Choi D, Alex B, Mulhall JP. Deformity stabilization and improvement in men with untreated Peyronie’s disease. BJU Int. 2014;113(1):133–136. doi: 10.1111/bju.12346
  13. Bilgutay AN, Pastuszak AW. Peyronie’s disease: What’s around the bend? Indian J Urol. 2016;32(1):6–14. doi: 10.4103/0970-1591.173107
  14. Chung E, Gillman M, Rushton D, et al. Prevalence of penile curvature: a population-based cross-sectional study in metropolitan and rural cities in Australia. BJU Int. 2018;122 Suppl 5:42–49. doi: 10.1111/bju.14605
  15. Chung E, Ralph D, Kagioglu A, et al. Evidence-based management guidelines on peyronie’s disease. J Sex Med. 2016;13(6):905–923. doi: 10.1016/j.jsxm.2016.04.062
  16. Dahm P, Jung JH, Bodie J. Moving from consensus- to evidence-based clinical practice guidelines for peyronie’s disease. J Sex Med. 2017;14(1):170–171. doi: 10.1016/j.jsxm.2016.10.015
  17. Dibenedetti DB, Nguyen D, Zografos L, et al. A population-based study of peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503. doi: 10.1155/2011/282503
  18. El-Sakka AI. Prevalence of Peyronie’s disease among patients with erectile dysfunction. Eur Urol. 2006;49(3):564–569. doi: 10.1016/j.eururo.2005.10.026
  19. Gao L, Qian S, Tang Z, et al. A meta-analysis of extracorporeal shock wave therapy for Peyronie’s disease. Int J Impot Res. 2016;28(5):161–166. doi: 10.1038/ijir.2016.24
  20. Gholami SS, Gonzalez-Cadavid NF, Lin CS, et al. Peyronie’s disease: a review. J Urol. 2003;169(4):1234–1241. doi: 10.1097/01.ju.0000053800.62741.fe
  21. Hatzichristodoulou G, Meisner C, Gschwend JE, et al. Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10(11):2815–2821. doi: 10.1111/jsm.12275
  22. Hussein AA, Alwaal A, Lue TF. All about Peyronie’s disease. Asian J Urol. 2015;2(2):70–78. doi: 10.1016/j.ajur.2015.04.019
  23. Kadioglu A, Tefekli A, Erol B, et al. A retrospective review of 307 men with Peyronie’s disease. J Urol. 2002;168(3):1075–1079. doi: 10.1097/01.ju.0000024040.55662.36
  24. Kadioglu A, Tefekli A, Erol B, et al. Color Doppler ultrasound assessment of penile vascular system in men with Peyronie’s disease. Int J Impot Res. 2000;12(5):263–267. doi: 10.1038/sj.ijir.3900569
  25. Lindsay MB, Schain DM, Grambsch P, et al. The incidence of Peyronie’s disease in Rochester. Minnesota, 1950 through 1984. J Urol. 1991;146(4):1007–1009. doi: 10.1016/s0022-5347(17)37988-0
  26. Liu T, Shindel AW, Lin G, Lue TF. Cellular signaling pathways modulated by low-intensity extracorporeal shock wave therapy. Int J Impot Res. 2019;31(3):170–176. doi: 10.1038/s41443-019-0113-3
  27. Masterson TA, Rezk A, Ramasamy R. Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie’s disease: a review of the literature. World J Urol. 2020;38(2):279–285. doi: 10.1007/s00345-019-02850-3
  28. Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171(6 Pt 1):2350–2353. doi: 10.1097/01.ju.0000127744.18878.f1
  29. Muller A, Mulhall JP. Peyronie’s disease intervention trials: methodological challenges and issues. J Sex Med. 2009;6(3):848–861. doi: 10.1111/j.1743-6109.2008.01081.x
  30. Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie’s Disease: AUA Guideline. J Urol. 2015;194(3):745–753. doi: 10.1016/j.juro.2015.05.098
  31. Nelson CJ, Mulhall JP. Psychological impact of Peyronie’s disease: A review. J Sex Med. 2013;10(3):653–660. doi: 10.1111/j.1743-6109.2012.02999.x
  32. Nelson CJ, Diblasio C, Kendirci M, et al. The chronology of depression and distress in men with Peyronie’s disease. J Sex Med. 2008;5(8):1985–1990. doi: 10.1111/j.1743-6109.2008.00895.x
  33. Nguyen HMT, Anaissie J, DeLay KJ, et al. Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute-phase peyronie’s disease. J Sex Med. 2017;14(10):1220–1225. doi: 10.1016/j.jsxm.2017.08.008
  34. Ostrowski KA, Gannon JR, Walsh TJ. A review of the epidemiology and treatment of Peyronie’s disease. Res Rep Urol. 2016;(8):61–70. doi: 10.2147/RRU.S65620
  35. Palmieri A, Imbimbo C, Creta M, et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35(2):190–195. doi: 10.1111/j.1365-2605.2011.01226.x
  36. Pryor JP, Ralph DJ. Clinical presentations of Peyronie’s disease. Int J Impot Res. 2002;14(5):414–417. doi: 10.1038/sj.ijir.3900877
  37. Russo GI, Milenkovic U, Hellstrom W, et al. Clinical efficacy of injection and mechanical therapy for peyronie’s disease: a systematic review of the literature. Eur Urol. 2018;74(6):767–781. doi: 10.1016/j.eururo.2018.07.005
  38. Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU Int. 2010;106(2):240–248. doi: 10.1111/j.1464-410X.2009.09041.x
  39. Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. Retraction statement: A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease. BJU Int. 2015;115(3):E10. doi: 10.1111/bju.13063
  40. Schwarzer U, Sommer F, Klotz T, et al. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001;88(7):727–730. doi: 10.1046/j.1464-4096.2001.02436.x
  41. Tal R, Heck M, Teloken P, et al. Peyronie’s disease following radical prostatectomy: incidence and predictors. J Sex Med. 2010;7(3):1254–1261. doi: 10.1111/j.1743–6109.2009.01655.x
  42. Ventimiglia E, Capogrosso P, Colicchia M, et al. Peyronie’s disease and autoimmunity-a real-life clinical study and comprehensive review. J Sex Med. 2015;12(4):1062–1069. doi: 10.1111/jsm.12825

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Gubanov E.S., Boryaev E.A., Stolyarov S.A., Zimichev A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).